Loading...
Trevi Therapeutics, Inc.
TRVI•NASDAQ
Healthcare
Biotechnology
$7.87
$0.03(0.38%)
Trevi Therapeutics, Inc. (TRVI) Financial Performance & Income Statement Overview
Review Trevi Therapeutics, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
0.00%
Operating Income Growth
-51.89%
↓ 51.89%
Net Income Growth
-64.84%
↓ 64.84%
Operating Cash Flow Growth
-20.64%
↓ 20.64%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-58.41%
↓ 58.41%
ROIC
-51.02%
↓ 51.02%
Trevi Therapeutics, Inc. (TRVI) Income Statement & Financial Overview
Review Trevi Therapeutics, Inc.'s (TRVI) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $38000.00 | $35000.00 |
| Gross Profit | $0.00 | $0.00 | -$38000.00 | -$35000.00 |
| Gross Profit Ratio | $0.00 | |||
| R&D Expenses | $9.33M | $11.22M | $10.02M | $8.80M |
| SG&A Expenses | $2.92M | $2.86M | $3.23M | $3.07M |
| Operating Expenses | $12.24M | $14.09M | $13.25M | $11.87M |
| Total Costs & Expenses | $12.24M | $14.09M | $13.29M | $11.91M |
| Interest Income | $843000.00 | $826000.00 | $935000.00 | $998000.00 |
| Interest Expense | $1000.00 | $1000.00 | $1000.00 | $1000.00 |
| Depreciation & Amortization | $38000.00 | $36000.00 | $38000.00 | $35000.00 |
| EBITDA | -$11.36M | -$13.24M | -$12.32M | -$10.87M |
| EBITDA Ratio | ||||
| Operating Income | -$12.24M | -$14.09M | -$13.29M | -$11.91M |
| Operating Income Ratio | ||||
| Other Income/Expenses (Net) | $844000.00 | $814000.00 | $929000.00 | $996000.00 |
| Income Before Tax | -$11.40M | -$13.27M | -$12.36M | -$10.91M |
| Income Before Tax Ratio | ||||
| Income Tax Expense | $16000.00 | -$31000.00 | -$8000.00 | -$8000.00 |
| Net Income | -$11.41M | -$13.24M | -$12.35M | -$10.90M |
| Net Income Ratio | ||||
| EPS | -$0.11 | -$0.13 | -$0.12 | -$0.11 |
| Diluted EPS | -$0.11 | -$0.13 | -$0.12 | -$0.11 |
| Weighted Avg Shares Outstanding | $106.010M | $101.04M | $101.04M | $99.52M |
| Weighted Avg Shares Outstanding (Diluted) | $106.010M | $101.04M | $101.04M | $99.52M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan